卡维地洛与倍他乐克防治大鼠AMI左室重构作用的比较

目的对比卡维地洛及倍他乐克对大鼠急性心肌梗死(AMI)左室重构(LVRM)的防治作用.方法 105只AMI术后成活的雌性SD大鼠随机分成AMI对照(n=35)、卡维地洛1 mg/(kg@d)(n=35)和倍他乐克2 mg/(kg@d)(n=35)三组.另设假手术组.给药4周后行血流动力学测定和病理分析.去除死亡及梗死面积＜35%或＞55%者,最终46只大鼠资料完整,在以上各组分别为11,12,11和12只.结果与假手术组相比,AMI组的左室舒张末压(LVEDP)、容积(LVV)、重量(LVW)显著增加(P＜0.05～0.111),左室内压最大上升和下降速率(±dp/dt)及其校正值(±dp/dt/LVSP)显著降低(P＜0.01～0.001).与AMI组相比,卡维地洛和倍他乐克组的LVEDP及LVV均显著降低(P均＜0.001),±dp/dt及±dp/dt/LVSP均显著升高(P＜0.05～0.001),而LVW和RVW仅在卡维地洛组显著减轻(P均＜0.05～0.01).结论 1、卡维地洛能有效抑制大鼠AMI左室重构并改善血流动力学和左室功能,2、倍他乐克与卡维地洛的作用相似,但对心室肥厚似无抑制作用.     

卡维地洛对急性心肌梗死后大鼠心室重塑及MMP/TIMP表达的影响

[目的]研究卡维地洛对大鼠心肌梗死后心室重塑及MMP/TIMP表达的影响。[方法]结扎大鼠左冠状动脉建立急性心肌梗死(AMI)模型,术后24 h存活大鼠随机分为心肌梗死对照组(MI组),卡维地洛干预组(C组),另设假手术组(S组)对照。C组给予卡维地洛[10 mg/(kg.d)]分两次直接灌胃,MI组和S组大鼠则予等量蒸馏水。4周后检测各组血流动力学、心室重塑指标。采用免疫组化法检测心室肌中MMP-8和TIMP-1的表达。[结果]与假手术组相比,MI组的左室舒张末压(LVEDP)、容积(LVV)、重量(LVW)明显增加,分别为(2.2±2.0)mmHg和(19.9±12.8)mmHg,(0.43±0.11)mL和(0.91±0.08)mL,(525±62)mg和(714±64)mg,P<0.01,MMP-8和TIMP-1表达明显增加(分别为35.5±0.27和97.6±0.21,43.6±0.24和89.5±0.21,P<0.01),而心率及各项心功能指标如左心室收缩压(LVESP)和左心室内压最大上升和下降速率(±dp/dt)及其校正值(±dp/dt/LVSP)明显降低(P<0.05~0.01);与MI组相...     

不同剂量卡维地洛防治大鼠急性心肌梗死左室重构的研究

目的对比观察不同剂量卡维地洛对大鼠急性心肌梗死(AMI)左室重构(LVRM)的防治作用。方法雌性SD大鼠AMI术后成活142只,分为AMI对照组(n=35),和卡维地洛大剂量(10mg·kg-1·d-1,n=37),中剂量(1mg·kg-1·d-1,n=35),及小剂量(0.1mg·kg-1·d-1,n=35)四组。另设假手术组对照。直接灌胃给药4周后行血流动力学测定、心脏标本固定及病理分析。去除梗死面积＜35％或＞55％者,最终58只大鼠资料完整。结果AMI各组间梗死面积均无显著差异(44.5％～46.3％,P均＞0.05)。与假手术组相比,AMI组的左室舒张末压(LVEDP)、容积(LVV)、实际左心室重量(LVAW)及相对重量(LVRW)均显著增加(P均＜0.01),左室球形指数和左室内压最大上升和下降速率(±dp/dt)及其校正值(±dp/dt/LVSP)均显著降低(P均＜0.01)。与AMI组相比,卡维地洛大、中、小剂量组的LVEDP、LVV、LVAW和LVRW均呈剂量相关性显著降低(LVEDP7.7mmHg±1.9mmHg,12.1mmHg±2.0mmHg,14.5mmHg±4.6mmHg对24.5mmHg±5.3mmHg;LVV0.72ml±0.10ml,0.79ml±0.08ml,0.82ml±0.10ml对0.92ml±0.11ml;LVAW589mg±57mg,622mg±70mg,666mg±57mg对730mg±79mg;P＜0.05～0.001),±dp/dt及±dp/dt/LVSP均显著增加(P＜0.05～0.01),但各剂量组间均无显著差异,左室球形指数仅在大剂量组显著改善(P＜0.05)。结论卡维地洛大、中、小剂量均能有效地防止大鼠AMI左室重构,改善血流动力学和左室功能;小剂量有效,大剂量更好。     

急性心肌梗塞后早期联合使用氯沙坦及与培多普利对左室重塑和左室功能改善的实验研究

目的 观察大鼠急性心肌梗塞(AMI)后24小时内联合使用氯沙坦与培多普利对心肌肥厚、左室功能的影响。方法 结扎左室冠状动脉造成大面积心肌梗塞,假手术大鼠只穿线不结扎,随机分为假手术组(S)、对照组(C)、氯沙坦组(L．15mg／kg)和联合用药组(LP,氯沙坦7．5mg/kg,培多普利1mg/kg),术后24小时内开始用药。5周后观察全心重量／体重、心率、血压及左室收缩压(LVSP)、左室舒张末压(LVEDP)、±dp／dt等指标。结果 (1)与S组比较,C组的垒心重量／体重明显增加(P<0．01),L和LP组则明显低于C组(P<0．05)．与S组无显差异。(2)与S组比较．C组和2个用药组的LVEDP明显升高而±dp,dt明显降低(P<0．001．P<0．01)。但2个用药组的LVEDP明显低于C组,而±dp／dt明显高于C组(P<0．001)。(3)各组之间的心率无显差异。与S组和C组比较,2个用药组的血压和LVSP明显降低。与L组比较,LP组舒张压和平均动脉压降低更明显(P<0．05)。结论．AMI后大鼠心脏重量增加,井且发生左心室功能障碍。氯沙坦、联合用药后可以减轻心肌重量的增加,改善左室功能障碍。     

伊伐布雷定对心肌梗死大鼠心肌细胞Notch和 NF-κB信号通路的影响

目的:探讨伊伐布雷定(IVA)对心肌梗死大鼠心肌细胞Notch和NF-κB信号通路的影响。方法:采用结扎冠状动脉左前降支建立心肌梗死模型,将存活大鼠随机分为模型组(MI组,n=8)和治疗组(IVA组,n=8)。以相同部位穿线但不结扎冠状动脉左前降支的大鼠作为对照组(CON组,n=8)。IVA给药28 d。检测所有大鼠血流动力学和心功能指标:心率(HR)、收缩压(SBP)、舒张压(DBP)、平均动脉压(MAP)、左室收缩压(LVSP)、左室舒张末压(LVEDP)和左室内压最大上升和下降速率(±dp/dt);左室重量指数、左室截面直径和心肌梗死面积;RT-PCR检测大鼠心肌细胞Notch信号通路成分mRNA的表达水平(Notch-1、Dll-4、Hes-1);Western-blot检测DICD-1蛋白和P65蛋白表达水平。组间比较采用单因素方差分析,两两比较采用SNK法。结果:MI组SBP、 DBP、MAP、LASP、LVEDP和±dp/dt均低于对照组(P<0.05);而IVA上述指标均高于MI组(P<0.05)。MI组左室重量指数和左室截面直径明显大于对照组(P<0.05),但小于IVA组(P<0.05)。MI组Notch-1 mRNA表达水平明显高于对照组(P<0.05),但低于IVA组(P<0.05)。3组Dll-4和Hes-1 mRNA表达水平的比较差异无统计学意义(P>0.05)。MI组心肌细胞NICD-1蛋白和P65蛋白表达水平明显高于CON组(P<0.05),但是低于IVA组(P<0.05)。结论:IVA可能通过Notch和NF-κB信号通路发挥改善心肌梗死大鼠心功能和抑制心室重构的作用。     

美托洛尔对心衰大鼠肌浆网Ca2+-ATP酶及心功能的影响

目的 探讨美托洛尔对心衰大鼠肌浆网Ca2+-ATP酶及心功能的影响.方法 腹主动脉缩窄法建立心衰大鼠模型,同时设假手术组.对心衰大鼠随机分为心力衰竭组及美托洛尔组10 mg/(kg·d),观察6周,行心脏超声、血流动力学检查及SERCA2a蛋白及活性测定.结果 同假手术组比较,心衰大鼠左室舒张末压(LVEDP)显著升高,短轴缩短率(FS)、左室收缩压(LVSP)、压力最大上升及下降速率(±dp/dt max)显著降低(P＜0.05),左室收缩、舒张末直径(LVESD/LVEDD),左室后壁厚度(LVPWD)、室间隔厚度(VSD)及左室质量指数(LVWI)显著增加(P＜0.05);美托洛尔治疗后,LVSP、±dp/dt max较心衰组显著增加(P＜0.05),LVEDD、VSD、LVWI显著减小(P＜0.05),但未达到假手术组水平(P＜0.05);同心衰组比较,美托洛尔对SERCA2a蛋白量无明显影响,能显著升高其活性(P＜0.05),但未达到假手术组水平(P＜0.05).结论 美托洛尔对SERCA2a蛋白量无明显影响,但能显著升高其活性,这可能是其改善心衰大鼠的心脏功能,抑制心肌重塑的机制之一.     

卡维地洛对心梗大鼠心肌病理形态和心肌细胞凋亡的影响

目的 :探讨心肌梗死 (MI)后心肌病理形态学和心肌细胞凋亡的变化、意义及卡维地洛 (CAR)治疗的作用机制。方法 :观察雄性Wistar大鼠MI后的血流动力学参数、心室重塑指标、心肌病理形态学及心肌细胞凋亡的改变 ,并于MI后 1周开始对大鼠进行 7周的CAR和美托洛尔 (MET)干预 ,观察CAR和MET对上述指标的影响。结果 :MI后大鼠MAP和±dp/dtmax显著降低 ,左室舒张期末压 (LVEDP)、左心室湿重 /体重 (LVW /BW)、右心室湿重 /体重 (RVW/BW )和心肌细胞凋亡指数明显增高 ,心肌出现明显病理形态学改变 ;CAR和MET可不同程度地改善MI大鼠心功能和心肌超微结构异常 ,CAR降低心肌细胞凋亡指数的效果优于MET。结论 :心肌细胞凋亡在MI后充血性心力衰竭的发生、发展过程中起着重要的作用 ,CAR可有效地减少MI后心肌细胞凋亡 ,改善心肌病理形态学异常     

卡维地洛对猪急性心肌梗死再灌注后无再流的影响

目的:评价卡维地洛防治猪急性心肌梗死(AMI)再灌注后无再流的作用.方法:将中华小型猪24只随机分成对照组、卡维地洛组1mg/(kg·d)和假手术组,每组8只.冠状动脉结扎3h,松解1h制备AMI再灌注模型.AMI前、后和再灌注后均行血流动力学测定和心肌声学造影(MCE)检查,最终行病理学分析.结果:①与AMI前相比,对照组AMI后3h主动脉收缩和舒张压(SBP和DBP)、左室收缩压(LVSP),心排量(CO)和左心室内压最大收缩和舒张变化速率(±dp/dtmax)均显著下降(P<0.05),肺毛细血管楔压(PCWP)和左室舒张末压(LVEDP)均显著升高(P<0.01);再灌注后1h仅LVSP显著恢复(P<0.05),±dp/dtmax继续显著下降(P<0.05);而卡维地洛组AMI后3h各项指标变化与对照组相同;但再灌注后1hLVSP,LVEDP,±dp/dtmax和CO均显著恢复(P<0.05)且比对照组更显著(P<0.05).②对照组MCE和病理染色所测的冠脉结扎区心肌范围(LA)高度一致,再灌注后无再流面积(ANR)分别为78.5%和82.3%,心肌坏死面积(NA)占LA的98.5%;而卡维地洛组%LA虽与对照组相当,但两方法所测ANR仅分别为24.9%和25.8%,NA仅为74.4%,均显著小于对照组(P<0.05).③对照组再灌注即刻和再灌注后1h冠脉血流量仅占AMI前的45.8%和50.6%(P<0.01),而卡维地洛组冠脉血流量分别提高到70.6%和74.1%,均比对照组显著增加(P<0.01).结论:卡维地洛能有效地防治AMI再灌注后无再流,改善其心功能,缩小梗死面积.     

肢体缺血预适应增强脂联素对心功能的保护作用

目的:研究肢体缺血预适应对缺血大鼠心肌是否具有保护作用。方法:健康雄性SD大鼠,体重220~280 g,随机分为3组(n=10),假手术组(sham组)只穿线,左冠状动脉前降支不予处理;心肌缺血2 h组(MI2h组):心脏冠状动脉左前降支实施缺血2 h;肢体缺血预适应组(LIPC组):肢体缺血5 min,再灌注5 min,连续预适应3天,第4天实施缺血2 h。RM6240记录实验各组心功能指标,Elisa检测血清脂联素。结果:MI2h组大鼠血清中脂联素的含量、LVSP和±dp/dtmax与sham组比较均降低明显(P<0.05);LIPC组大鼠血清中脂联素的含量、LVSP和±dp/dtmax较MI2h组升高(P<0.05);与sham组相比,MI2h组LVEDP明显升高(P<0.05),与MI2h相比LIPC组LVEDP数值降低显著(P<0.05);血清脂联素水平与心收缩功能指标呈显著正相关。结论:脂联素与肢体缺血预适应作为正性调节因素,共同在心肌缺血损伤心肌病变的发生、发展中起作用。     

ICI174,864对创伤失血性休克大鼠血流动力学指标的影响及其与垂体的关系

目的　探讨δ阿片受体特异性拮抗剂ICI1 74 ,86 4对创伤失血性休克大鼠血流动力学指标的影响及其与垂体的关系。方法　复制大鼠创伤失血性休克模型 ,观察ICI1 74 ,86 4对血压 (MAP) ,左室内压 (LVSP) ,左室内压最大变化速率 (±dp/dt max)等血流动力学指标的影响及垂体摘除对ICI1 74 ,86 4作用的影响。结果　ICI1 74 ,86 4 (5 0mg,2 0ml)侧脑室给药可显著升高创伤失血性休克大鼠的MAP、LVSP、±dp/dtmax等血流动力学指标。垂体摘除可取消ICI1 74 ,86 4的上述作用。结论　δ阿片受体特异性拮抗剂ICI1 74 ,86 4对创伤失血性休克心血管功能指标有较好的的改善作用 ,ICI1 74 ,86 4的这一作用与垂体的完整性密切相关。     

Effect of carvedilol on cardiac function and left ventricular remodeling in rats after acute myocardial infarction

Objective: To observe the effect of carvedilol injection on left ventricular function and collagen remodelingin rat with myocardial infarction. Methods: Sixty rats with a model of myocardial infarction were randomly divided intonine groups. The rats of therapeutical group were treated with carvedilol injection (2 mg/d intraperitoneal injection)and/or captopil (2 g/L drinking water). Acute myocardial infaction (AMI) group did not receive drug treatment. Theanimals were sacrificed at 4 weeks and 8 weeks after coronary artery ligation. The levels of plasma angiotensin Ⅱ andplasma aldosterone and left ventricle function were determined at different time. The collagen content and the raio of     

卡维地洛对急性心肌梗死大鼠心肌细胞外基质重塑的影响

目的:研究卡维地洛对急性心肌梗死(AMI)后大鼠心肌细胞外基质(ECM)重塑的影响。方法:在体结 扎Wistar大鼠冠状动脉左前降支建立AMI模型,存活24h者随机分为卡维地洛治疗组(n=11)和AMI组(n= 12),另以仅穿线不结扎左前降支建立假手术组(n=10)。卡维地洛治疗组给予卡维地洛10mg/(kg·d)灌胃,2 次/d;AMI组和假手术组仅给予同体积生理盐水灌胃,2次/d。4周末用半定量RT PCR法检测各组大鼠左室心肌 非梗死区基质金属蛋白酶MMP- 2和MMP 9mRNA表达,采用明胶酶谱法测定2者活性,采用苦味酸 酸性品红染 色测定心肌总胶原,计算胶原容积分数(CVF)。结果:AMI组大鼠心肌非梗死区MMP 2、MMP -9mRNA表达及活 性,以及CVF均较假手术组增加(P<0.01),而卡维地洛治疗组上述指标均低于AMI组(P<0.01)。结论:卡维地 洛可改善心肌梗死后非梗死区心肌细胞外基质重塑,这可能是其对心肌梗死有益作用的机制之一。     

急性心肌梗死病人早期大剂量应用美托洛尔的疗效分析

目的:观察急性心肌梗死病人早期大剂量应用美托洛尔的疗效。方法:将173例急性心肌梗死病人随机双盲分为治疗组和对照组。治疗组在对照组常规治疗的基础上早期大剂量应用美托洛尔,比较两组心原性猝死、再发心梗、心原性休克、死亡率指标的变化。结果:急性心肌梗死病人早期大剂量应用美托洛尔治疗心原性猝死、梗死后再梗死发生率治疗组低于对照组(P<0.01),心原性休克发生率对照组低于治疗组(P<0.01)。两组总死亡率无显著性差异(P>0.05)。结论:急性心肌梗死病人早期大剂量应用美托洛尔治疗可减少心原性猝死、再发心梗的发生率,增加心原性休克的发生率。     

Myocardial autophagy variation during acute myocardial infarction in rats: the effects of carvedilol

Background The loss of cardiac myocytes is one of the mechanisms involved in acute myocardial infarction （AMI）-related heart failure. Autophagy is a common biological process in eukaryote cells. The relationship between cardiac myocyte loss and autophagy after AMI is still unclear. Carvedilol, a non-selective α1-and β-receptor blocker, also suppresses cardiac myocyte necrosis and apoptosis induced by ischemia. However, the association between the therapeutic effects of carvedilol and autophagy is still not well understood. The aim of the present study was to establish a rat model of AMI and observe changes in autophagy in different zones of the myocardium and the effects of carvedilol on autophagy in AMI rats. Methods The animals were randomly assigned to a sham group, an AMI group, a chloroquine intervention group and a carvedilol group. The AMI rat model was established by ligating the left anterior descending coronary artery. The hearts were harvested at 40 minutes, 2 hours, 24 hours and 2 weeks after ligation in the AMI group, at 40 minutes in the chloroquine intervention group and at 2 weeks in other groups. Presence of autophagic vacuoles （AV） in the myocytes was observed by electron microscopy. The expression of autophagy-, anti-apoptotic- and apoptotic-related proteins, MAPLC-3, Beclin-1, Bcl-xl and Bax, were detected by immunohistochemical staining and Western blotting. Results AVs were not observed in necrotic regions of the myocardium 40 minutes after ligation of the coronary artery. A large number of AVs were found in the region bordering the infarction. Compared with the infarction region and the normal region, the formation of AV was significantly increased in the region bordering the infarction （P 〈0.05）. The expression of autophagy- and anti-apoptotic-related proteins was significantly increased in the region bordering the infarction. Meanwhile, the expression of apoptotic-related proteins was significantly increased in the infarction region. In the chloroquine intervention group, a large number of initiated AVs （AVis） were found in the necrotic myocardial region. At 2 weeks after AMI, AVs were frequently observed in myocardial cells in the AMI group, the carvedilol group and the sham group, and the number of AVs was significantly increased in the carvedilol group compared with both the AMI group and the sham group （P 〈0.05）. The expression of autophagy- and anti-apoptotic-related proteins was significantly increased in the carvedilol group compared with that in the AMI group, and the positive expression located in the infarction region and the region bordering the infarction. Conclusions AMI induces the formation of AV in the myocardium. The expression of anti-apoptosis-related proteins increases in response to upregulation of autophagy. Carvedilol increases the formation of AVs and upregulates autophagy and anti-apoptosis of the cardiac myocytes after AMI.     

High-frequency ultrasound evaluation of effects of early treatment with metoprolol on myocardial inflammatory cytokine expression in rats with acute myocardial infarction

This study evaluated the effects of early treatment with β-adrenergic blocker metoprolol on ventricular remodeling and function after acute myocardial infarction (AMI) by using high frequency ultrasound.The relationship between the efficacy and the expression level of cardiac myocardial inflammatory cytokine was examined in rats.The rat model of AMI was induced by ligating the left ante-rior descending artery.The surviving rats were randomly assigned to two experimental groups:MI control (MI) group and MI metoprolol (MI-B) group,with the rats undergoing sham operation serving as normal control (Sham).MI-B group was given metoprolol for 4 weeks (refer to the CCS-2 protocol) and the other two groups received equal volume of saline via intragastric (i.g.) administation.The ventricular remodeling and function were evaluated by high frequency ultrasound 4 weeks after the treatment.Then all rats were sacrificed for pathological examination and immunohistochemistrical detection of inflammatory cytokines,including IL-1β,IL-6,IL-10 and TNF-α.Compared with the MI group,the left ventricular end-systolic dimension,end-diastolic dimension,end-systolic volume and end-diastolic volume of the MI-B group were significantly decreased (P<0.01),while the left ventricular anterior wall end-diastolic thickness,ejection fraction and fractional shortening were obviously increased (P<0.01).The conspicuous improvement in the left ventricular morphology and function was coincident with the markedly reduced TNF-α and IL-1β expression and the increased IL-10 expression.We are led to conclude that early metoprolol treatment for AMI can regulate myocardial inflammatory cytokine expression to improve cardiac function and the underlying mechanism might be that it decreases the level of pro-inflammatory cytokines and increases the level of its anti-inflammatory counterparts in cardiac myocytes.Our study also showed that echocardiography is a useful technique for the structural and functional assessment of left ventricle after acute my     

卡维地洛对家兔急性心肌梗死左室重构的作用

目的评价第三代β-受体阻滞剂卡维地洛对家兔急性心肌梗塞(AMI)后的左室重构的防治作用,以及对梗死区损伤心肌细胞的修复.方法采用家兔制备心肌梗死模型,20只AMI术后成活的雄性家兔随机分为AMI对照组、卡维地洛(CVD)组,另设假手术组.灌胃给药4周后处死动物.用电子精确天平称量左室、右室的重量,用羟脯氨酸方法测定心肌组织的胶原的含量及采集标本进行病理分析.结果梗死后左心室、右心室重量均比假手术组增加,差异显著.梗死区胶原含量显著增加,非梗死区胶原含量增加明显.经卡维地洛治疗后,左心室、右心室重量均下降,但未能恢复至正常水平.梗死区胶原含量亦略有下降,但差异不显著.非梗死区胶原含量下降明显,差异显著.病理分析结果显示卡维地洛组心肌细胞损伤程度减轻.结论卡维地洛能有效防治家兔AMI后的左室重构及减轻心肌细胞损伤程度.     

胺碘酮联合美托洛尔治疗心律失常疗效分析

目的:探讨胺碘酮联合小剂量美托洛尔治疗急性心肌梗死伴室性心律失常的有效性和安全性。方法:将82例AMI伴室性心律失常的患者随机分为胺碘酮联合美托洛尔组(治疗组42例)与胺碘酮组(对照组40例),治疗6个月,观察两组心律失常好转情况及心功能改善情况。结果:治疗组抗心律失常有效率及心功能改善情况均优于对照组(P<0.05)。结论:胺碘酮联合小剂量美托洛尔治疗AMI并室性心律失常疗效好,使用安全,无明显副作用。     

β-受体阻滞剂促大鼠缺血心肌血管新生的实验研究

目的：评价β－受体阻滞剂是否有促进缺血心肌血管新生的作用并探讨其发生机制。方法：将急性心肌梗塞1周后的大鼠分别用美托洛尔灌胃1－3周,用免疫组织化学法检测缺血心肌中毛细血管内皮细胞及VEGF,并计数毛细血管密度,同时观察心率的变化,结果：服用美托洛尔后的大鼠缺血心肌中毛细血管密度和VEGF蛋白表达明显增加;用美托洛尔后心率下降显著的心肌梗塞大鼠,其缺血心肌中毛细血管密度和VEGF表达又显著高于心率下降不明显的大鼠,结论：β－受体阻滞剂可以促进缺血心肌毛细血管新生,该作用可能是由窦性心动缓触发的内源性VEGF分泌增加所致。     

基质金属蛋白酶9与血浆脑钠素在大鼠急性心肌梗死后的表达

目的:研究急性心肌梗死(AMI)后血浆脑钠素(BNP)与基质金属蛋白酶9(MMP-9)的表达变化及相关关系,探讨血浆BNP浓度与AMI后左室重构的关系.方法:SD大鼠随机分为对照组、心肌梗死后1 d组、心肌梗死后1 w组、心肌梗死后2 w组、心肌梗死后4 w组.结扎大鼠冠状动脉前降支制作AMI模型.行血流动力学检测后,测定各组大鼠血浆BNP浓度及MMP-9,后处死大鼠,取心肌标本测定梗塞面积及心肌胶原含量.结果:心肌梗死各组较对照组左心室舒张末压均显著增加(P＜0.05),平均动脉压、左心室内压最大上升和下降速率则显著降低(P＜0.01);第4周组左心室湿重较其余各组明显增加(P＜0.01).心肌梗死各组BNP、MMP-9表达较同期对照组显著增加(P＜0.01),MMP-9与BNP呈正相关(r=0.81,P＜0.01);心肌胶原含量增加,与左心室内压最大上升和下降速率呈负相关.结论:心梗后BNP与MMP-9明显升高呈动态改变,并且与心室重构及心功能密切相关,心梗后BNP的迅速分泌可能是促进MMP-9表达的原因之一;心梗后同时测定BNP与MMP-9浓度对于判断心功能及心室重构从而间接判断预后有重要意义.